Precigen, Inc.

Precigen, Inc.

PGENNYSE / NASDAQHealthcareSmall cap

$4.21+$0.05 (+1.2%)

Last close · Data as of Nov 20, 2026

Market cap
$1.4B
P/E
-5.5x
EV / EBITDA
-5.9x
Revenue
$9.7M
Net margin
-2588.2%
ROCE
-90.2%

+7.9% over the last year

Precigen, Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
-38.4%
3M
-43.4%
6M
-1.4%
1Y
+7.9%
5Y
+12.0%

52-week range

Day change +$0.05 (+1.2%) from $4.16 to $4.21 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in PGEN, bought on each weekday since 2021.

News & filings

What Precigen filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

ConcernThe company made a net loss of 251 million US dollars in fiscal 2025.

Strengths (1)

  • Revenue more than doubled in fiscal 2025.
  • Shareholders' equity is small against the company's size, so return on equity and debt to equity are not shown.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

Precigen, Inc.,a discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases.

Read moreShow less

Precigen, Inc.,a discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases. The company offers therapeutic platforms consisting of AdenoVerse platform, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1/1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV+ solid tumors; and PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis. Further, it provides UltraPorator, a proprietary electroporation device. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.

Sector
Healthcare
Shares outstanding
353.9M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$1.4B
P/E
-5.5x
P/B
65.8x
EV / EBITDA
-5.9x
EV / Sales
149.1x
P/S
142.1x
52-week high
$8.56
52-week low
$3.10

Profitability

Operating margin
-1100.8%
Net margin
-2588.2%
EBITDA margin
-2515.2%
ROE
-1198.6%
ROCE
-90.2%
ROIC
-219.1%
ROA
-161.2%
Asset turnover
0.06

Growth

Revenue
$9.7M
Revenue growth, 1Y
146.7%
Revenue CAGR, 3Y
-28.9%
Net profit growth, 1Y
98.6%
Free cash flow
-$89.8M

Solvency

Current ratio
3.09
Debt / Equity
4.70
Debt / Assets
0.63
CFO / Net profit
0.35
Cash / Market cap
2.2%

Where the revenue went

FY2025 ended in a loss, so the lines are listed rather than drawn as a flow.

LineFY2025
Revenue$9.7M
Cost of revenue$4.8M
Gross profit$4.9M
Operating expenses$111.5M
Research and development$41.3M
Selling, general and administrative$70.1M
Operating income-$106.6M
Interest and other-$144.0M
Pretax income-$250.6M
Tax and other$0.00
Net income-$250.6M

Revenue and net profit

Revenue grew 146.7% in FY2025; net profit is the dashed line.

Precigen, Inc. revenue and net profit by fiscal year
Precigen, Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$26.9M$28.3M
FY2023$6.2M-$95.9M
FY2024$3.9M-$126.2M
FY2025$9.7M-$250.6M

Cash flows

FY2025: -$87.8M from operations, -$89.8M free after investment (dashed).

Precigen, Inc. operating and free cash flow by fiscal year
Precigen, Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022-$65.0M-$70.0M
FY2023-$66.9M-$68.5M
FY2024-$68.2M-$76.8M
FY2025-$87.8M-$89.8M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$9.7M+146.7%1Y
EBITDA
-$243.6M
Net profit
-$250.6M
Cash from operations
-$87.8M
Free cash flow
-$89.8M
Revenue CAGR, 3Y
-28.9%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$9.7M-$243.6M-$250.6M-$89.8M-1198.6%+146.7%+98.6%

Monthly returns

Month-by-month returns of PGEN across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$155.5M
Liabilities$134.6M
Equity$20.9M
Paid-in capital$2.4B
Retained earnings-$2.3B

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; PGEN highlighted.

P/E against peers

Most of this group is loss-making, so EV / Sales is compared for the companies without a P/E.

EV / Sales, for the companies without earnings

  1. Precigen, Inc. (this company)149.1x

Not shown (no positive earnings and no EV / Sales): Maze Therapeutics, Inc., MapLight Therapeutics, Inc., Bicara Therapeutics Inc.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
Precigen, Inc.PGENthis company$1.4B-5.5x65.8x-1198.6%-5.9x
Maze Therapeutics, Inc.MAZE$1.4B-10.7x4.0x-36.9%-8.8x
Healthcare Services Group, Inc.HCSG$1.4B23.8x2.8x11.6%14.9x
AtriCure, Inc.ATRC$1.4B-120.6x2.8x-2.3%79.2x
Integra LifeSciences Holdings CorporationIART$1.4B-2.6x1.3x-49.5%-9.7x
MapLight Therapeutics, Inc.MPLT$1.4B—3.0x-35.2%—
Butterfly Network, Inc.BFLY$1.4B—6.9x-39.3%—
UroGen Pharma Ltd.URGN$1.3B-8.8x-12.7x145.5%-10.0x
Bicara Therapeutics Inc.BCAX$1.3B-9.7x3.3x-34.4%-8.0x
Peer median—-9.2x2.9x-34.8%-8.4x

Year-to-date ROI

PGEN since 1 January, against earlier years.

Historical volatility

PGEN's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

Precigen, Inc. operating margin by fiscal year
Precigen, Inc. operating margin by fiscal year
DateOperating margin
FY2022-277.3%
FY2023-1429.6%
FY2024-2415.8%
FY2025-1101.2%
LineFY2025
Cost of revenueCost Of Revenue$4.8M
Gross profitGross Profit$4.9M
Operating expensesOperating Expense$111.5M
Research and developmentResearch And Development$41.3M
Selling, general and administrativeSelling General And Administration$70.1M
Total expensesTotal Expenses$116.3M
Pretax incomePretax Income-$250.6M

Learn while you research

Academy chapters picked for Precigen, Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Growth Investing147% revenue growth is in the top tier, learn how to value growth.7 min read
  3. 03 Leverage RatiosDebt/Equity of 4.70 is elevated, understand what that means for solvency.6 min read
  4. 04 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
  5. 05 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  6. 06 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
Browse the full Equiscale Academy →